Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
six
months ended in Dec. 2025, Sinopharm Group Cospent$125 Mil on purchasing property, plant, equipment.
It gained$2 Mil from selling property, plant, and equipment.
It spent$0 Mil on purchasing business.
It gained$18 Mil from selling business.
It spent$0 Mil on purchasing investments.
It gained$3 Mil from selling investments.
It paid$10Mil for net Intangibles purchase and sale.
And it received$52 Mil from other investing activities.
In all, Sinopharm Group Cospent$61 Mil on investment activities in financial market and operating subsidiaries for the
six
months ended in Dec. 2025.
Sinopharm Group Co's purchase of property, plant, equipment for the
six
months ended in Dec. 2025 was $-125 Mil. It means Sinopharm Group Co spent $125 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Sinopharm Group Co's sale of property, plant, equipment for the
six
months ended in Dec. 2025 was $2 Mil. It means Sinopharm Group Co gained $2 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Sinopharm Group Co's purchase of business for the
six
months ended in Dec. 2025 was $0 Mil. It means Sinopharm Group Co spent $0 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Sinopharm Group Co's sale of business for the
six
months ended in Dec. 2025 was $18 Mil. It means Sinopharm Group Co gained $18 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Sinopharm Group Co's purchase of investment for the
six
months ended in Dec. 2025 was $0 Mil. It means Sinopharm Group Co spent {stock_data.stock.currency_symbol}}0 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Sinopharm Group Co's sale of investment for the
six
months ended in Dec. 2025 was $3 Mil. It means Sinopharm Group Co gained $3 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Sinopharm Group Co's net Intangibles purchase and sale for the
six
months ended in Dec. 2025 was $-10 Mil.
It means Sinopharm Group Co paid $10 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Sinopharm Group Co's cash from discontinued investing activities for the
six
months ended in Dec. 2025 was 0 Mil.
It means Sinopharm Group Co paid $0 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Sinopharm Group Co's cash from other investing activities for the
six
months ended in Dec. 2025 was $52 Mil.
It means Sinopharm Group Co received $52 Mil from other investing activities.
Sinopharm Group Co Cash Flow from Investing Related Terms
Sinopharm Group Co Cash Flow from Investing Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Cash Flow from Investing Calculation
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Sinopharm Group Co's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-135 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Investing of $-135 Mil mean?
Sinopharm Group Co (SHTDF) has a Cash Flow from Investing of $-135 Mil as of Dec. 2025. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's Cash Flow from Investing too high?
Sinopharm Group Co's current Cash Flow from Investing is $-135 Mil. Overall, Sinopharm Group Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Cash Flow from Investing compare to MCK and COR?
Sinopharm Group Co's Cash Flow from Investing of $-135 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Medical Distribution company?
A good Cash Flow from Investing depends on the Medical Distribution industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Sinopharm Group Co and its competitors. Sinopharm Group Co's current Cash Flow from Investing is $-135 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.83, compared to a current price of $2.13 — trading 24.6% below its estimated fair value. The current Cash Flow from Investing is $-135 Mil. Sinopharm Group Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Cash Flow from Investing is $-135 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 24.6% below its estimated GF Value™ of $2.83.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Cash Flow from Investing: $-135 Mil
GF Value™: $2.83 vs. price of $2.13 (24.6% below fair value)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
76GF Score
Get the complete analysis for SHTDF
Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
